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The clinical relevance of early identification
and treatment of sleep disorders in mental
health care: protocol of a randomized
control trial
Fiona M. ter Heege1, Teus Mijnster1, Maaike M. van Veen1, Gerdina H. M. Pijnenborg1,2, Peter J. de Jong3,
Gretha J. Boersma1 and Marike Lancel1,3*
Abstract
Background: Sleep disorders are a risk factor for developing a variety of mental disorders, have a negative impact
on their remission rates and increase the risk of relapse. Early identification and treatment of sleep disorders is
therefore of paramount importance. Unfortunately, in mental health care sleep disorders are often poorly
recognized and specific treatment frequently occurs late or not at all. This protocol-paper presents a randomized
controlled trial investigating the clinical relevance of early detection and treatment of sleep disorders in mental
health care. The two aims of this project are 1) to determine the prevalence of sleep disorders in different mental
disorders, and 2) to investigate the contribution of early identification and adequate treatment of sleep disorders in
individuals with mental disorders to their sleep, mental disorder symptoms, general functioning, and quality of life.
Methods: Patients newly referred to a Dutch mental health institute for psychiatric treatment will be screened for
sleep disorders with the self-assessment Holland Sleep Disorders Questionnaire (HSDQ). Patients scoring above the
cut-off criteria will be invited for additional diagnostic evaluation and, treatment of the respective sleep disorder.
Participants will be randomly assigned to two groups: Immediate sleep diagnostics and intervention (TAU+SI-T0), or
delayed start of sleep intervention (TAU+SI-T1; 6 months after inclusion). The effect of sleep treatment as add-on to
treatment as usual (TAU) will be tested with regard to sleep disorder symptoms, general functioning, and quality of
life (in collaboration with a psychiatric sleep centre).
Discussion: This trial will examine the prevalence of different sleep disorders in a broad range of mental disorders,
providing information on the co-occurrence of specific sleep and mental disorders. Further, this study is the first to
investigate the impact of early treatment of sleep disorders on the outcome of many mental disorders. Moreover,
standard sleep interventions will be tailored to specific mental disorders, to increase their efficacy. The results of this
trial may contribute considerably to the improvement of mental health care.
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Background
Sleep problems are among the most frequent complaints
in individuals with a mental disorder. Therefore, sleep
disorders are common in individuals with mental disor-
ders. Chronic insomnia, for example, is estimated to
affect more than 40% in schizophrenia spectrum disor-
ders [1], compared to approximately 6% in the general
population [2]. Furthermore, insomnia complaints were
reported in more than 50% in individuals with an
affective disorder [3]. Six categories of clinical sleep dis-
orders are identified in the International Classification of
Sleep disorders (ICSD-3); insomnia, sleep related breath-
ing disorders (SRBD), central disorders of hypersomno-
lence (hypersomnia), circadian rhythm sleep-wake
disorders (CRSD), parasomnias, and sleep-related move-
ment disorders [4]. Although insomnia prevalence has
been investigated in connection with several different
mental disorders, prevalence rates for the other categor-
ies of sleep disorders have been less or not at all studied
in connection to the presence of mental disorders. More
detailed information on the prevalence of a certain sleep
disorder in connection to particular mental disorders
could improve treatment strategies and may even lead to
the identification of novel etiological pathways under-
lying the respective sleep disorders.
Studies suggest that sleep disorders increase the risk
for the development of mental disorders, and worsen
treatment outcome [5–7]. For instance, insomnia has
been shown to have prognostic validity for the develop-
ment of posttraumatic stress disorder (PTSD) [6, 8] and
depression [9, 10]. Moreover, the already high vulner-
ability for suicidal behavior in individuals with mental
health problems is further increased in those with poor
sleep [11, 12]. Thus, early and adequate treatment of
sleep disorders in individuals with mental disorders may
be of paramount importance, and might well lead to bet-
ter mental health outcomes and improved quality of life.
Despite the widespread use of sleep medication in
psychiatry, cognitive behavioral therapy for insomnia
(CBT-I) is currently considered the first-choice treat-
ment of chronic insomnia. CBT-I consists of psychoedu-
cation, sleep hygiene, relaxation training, stimulus
control therapy, sleep restriction therapy and cognitive
therapy. CBT-I is safe and effective (reviewed in [13]),
with superior long-term effects compared to sleep medi-
cation (in [14]). In individuals with both insomnia and
depression, CBT-I was found to both alleviate insomnia
complaints and reduce depression severity [15–18]. Fur-
thermore, in individuals suffering from posttraumatic
nightmares, the treatment of nightmares with imagery
rehearsal therapy (IRT) showed promising results in re-
ducing both insomnia and nightmare frequency, as well
as other global PTSD symptoms [19]. Although these
standard sleep disorder treatments are successful in the
general population, within individuals with mental disor-
ders problems with compliance may arise, for example
because the commonly used procedures may elicit dis-
tress that interferes with the efficacy of treatment.
Therefore, treatment protocols used in this study were
adapted to better fit the targeted population.
Despite a high occurrence of sleep disorders and
established negative effects on mental health, little atten-
tion is paid to sleep problems in mental health care.
Sleep disorders are frequently diagnosed years after on-
set; years in which poor sleep already exerted detrimen-
tal effects on physical and mental health, daytime
functioning and quality of life. Clearly, a lot can be
gained in mental health care by a timely delivery of sleep
disorder treatment. This paper presents the protocol of
a randomized controlled trial, in which the prevalence of
distinct sleep disorders will be assessed and the clinical
relevance of early sleep disorder treatment in mental
health care will be tested.
Aims and objectives
The overall aim of this study is to investigate the clinical
relevance of early identification and adequate treatment
of sleep disorders that co-occur with mental disorders.
The primary objectives of the study are to investigate:
1) The prevalence of the different six categories of
sleep disorders (insomnia, SRBD, hypersomnia, CRSD,
parasomnias, and sleep-related movement disorders) in
connection to specific mental disorders.
2) Whether screening for and early treatment of sleep
disorders exerts positive effects on sleep, treatment out-
comes (symptom severity/remission of mental disorder),
and quality of life.
Sex differences in both sleep and mental disorders are
common; therefore, the effect of sleep disorder treat-
ment may differ between the sexes. Based on this, a sec-
ondary objective of this study is to investigate whether
there is an interaction effect between sex and treatment
of sleep disorders on sleep, mental disorders symptoms
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This study is designed as a randomized controlled trial
in order to test the effects of early interventions for sleep
disorders on both sleep problems and mental health out-
come. Participants will be asked to complete several
questionnaires concerning sleep, quality of life, general
functioning and specific mental disorder symptomatol-
ogy, at three different time points over the course of
twelve months. Researchers and study participants are
not blinded to the conditions of the study.
Study population
All treatment seeking individuals who are newly regis-
tered at GGZ Drenthe Mental Health Institute (GGZ
Drenthe, Assen, NL; https://ggzdrenthe.nl/) will be asked
to participate in this study by their treating therapist.
The population of this mental health institute consists of
individuals diagnosed with a variety of mental health dis-
orders. Most individuals are diagnosed with chronic
and/or complex mental disorders and often present with
co-morbid disorders. Based on the participants’ main
diagnosis according to the Diagnostic and Statistical
Manual of Mental disorders - Fifth edition (DSM–5)
[20], participants will be subdivided into the following
diagnostic groups: depressive disorder, bipolar disorder,
anxiety disorder, PTSD, attention deficit (hyperactivity)
disorder (AD(H)D), autism spectrum disorder (ASD),
schizophrenia spectrum disorder (SSD), or personality
disorder. Patients under the age of 18, unable to ad-
equately read or speak Dutch, and/or deemed unfit (by
their therapist) to fill out questionnaires will be excluded
from the study.
Procedure
As part of the intake procedure of the mental health in-
stitute, routine outcome assessment (ROA) measure-
ments are conducted in most departments of the
institute, using an established online platform [21]. We
will use this infrastructure, to reduce the burden to the
participants and ensure data quality. Participants will be
asked to complete questionnaires prior to the intake
procedure (T0), 6 (T1), and 12 (T2) months later.
To screen for sleep disorders, patients fill out the Hol-
land Sleep Disorders Questionnaire (HSDQ) [22, 23]. Pa-
tients who score above the cut-off score for any specific
category of sleep disorders will be invited to participate
in this study. After being informed about the study pro-
cedures, they will be asked for informed consent.
For both the experimental and control conditions,
participants will continue their treatment as usual
(TAU) throughout the study. After stratification for
type of mental disorder, participants will be randomly
assigned (using Sealed Envelope software) to either
the experimental or control condition. In the experi-
mental condition sleep intervention(s) (SI) will start
immediately at T0 (TAU+SI-T0). In the control con-
dition, the sleep intervention(s) will first start six
months after inclusion, at T1 (TAU+SI-T1). This al-
lows to test the effects of early interventions for sleep
disorders on mental disorder symptoms, general func-
tioning, sleep, and quality of life. Sleep interventions
generally start with extensive diagnostic evaluation,
followed by patient-targeted sleep treatment. For indi-
viduals scoring below the cut-off score for a sleep dis-
order on the HSDQ, participation is limited to filling
out the questionnaires at T0. An exception to rando-
mised allocation will be made for participants in the
control condition whose HSDQ result or intake inter-
view indicates a very severe sleep disorder, such as
Narcolepsy. These participants will be immediately re-
ferred to a sleep centre, regardless of original
randomization. These patients will be included in the
prevalence estimate, but excluded from the analysis of
the treatment effects. An overview is provided in
Fig. 1.
This research project will be conducted in collabor-
ation with a sleep centre for psychiatry. Anamnestic in-
terviews, diagnostic assessments and sleep interventions
will be provided by trained staff.
Study outcomes
Primary outcomes are 1) the prevalence of different
sleep disorders as a function of individuals’ mental disor-
ders (depressive disorder, bipolar disorder, anxiety dis-
order, PTSD, AD(H)D, ASD, SSD or personality
disorder), and 2) the effect of sleep interventions on
sleep, severity of specific symptoms of mental disorders,
general functioning, and quality of life. Secondary out-
comes are 1) the effects of sleep interventions on object-
ive outcome parameters, for example use of sleep/
sedative medication, number of hospitalizations and
length of stay and, 2) differences between genders in the
prevalence of specific sleep disorders and sleep interven-
tion effects.
First, we expect that the prevalence of most sleep dis-
orders among individuals with mental disorders will ex-
ceed those in the general population. Second,
concerning the adjusted sleep interventions, we expect
that the treatment of sleep disorders, tailored to mental
disorders, will improve sleep, recovery from mental dis-
order symptoms, and quality of life in most patients. We
hypothesize that the effect of added sleep intervention(s)
will be larger than the effect of TAU alone in the TAU-
SI-T1 group.
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Measures/ materials
All scales used in this study will be administered in the
Dutch language and have been validated for use in
Dutch.
Sleep
The HSDQ [22] is a 32-item self-assessment question-
naire for sleep disorders, based on the International
Classification of Sleep disorders (ICSD-2) [24]. Each
item consists of a self-description (i.e. “I have difficulty
falling asleep”) and participants are instructed to re-
spond on a 5-point Likert scale indicating if the stated
item applies to them for the past 3 months (1= “not at
all”, 2 = “usually not”, 3 = “sometimes”, 4 = “usually”,
5 = “completely”). This questionnaire is validated (Cron-
bach’s alpha (α) = .90) [22] and screens for the following
categories of sleep disorders: Chronic insomnia (α = .92),
parasomnia (α = .85), CRSD (α = .84), hypersomnia
(α = .78), sleep-related movement disorders (i.e. restless
legs syndrome (RLS)) (α = .81), and SRBD (i.e. obstruct-
ive sleep apnea (OSA)(α = .62)) [23]. The total score of
the HSDQ distinguishes individuals with a clinically di-
agnosed sleep disorder from individuals without sleep
complaints (area under the curve, P(A) = .95) and the
diagnostic accuracy of the HSDQ is high (kappa = .80)
[22]. In the present study, the HSDQ will be used for
screening purposes and to assess sleep disorder preva-
lences. Mean scores will be calculated and the following
cut-off criteria will be used: Sleep disorder > 2.02;
chronic insomnia > 3.68; parasomnia > 2.42; CRSD >
3.42; hypersomnia > 2.9; sleep-related movement dis-
order > 2.7; SRBD > 2.87 [22]. For the analysis of sleep
treatment effect on response of the clinical sleep disor-
der(s), the HSDQ total and subscale scores will be used
as outcome variables.
Quality of life
Manchester Short Assessment of Quality of Life
(MANSA) The MANSA will be used to assess quality of
life. The MANSA is a 16-item self-rating scale with suffi-
cient internal consistency (α = .74) [25]. The question-
naire addresses the following aspects: Living
circumstances, work circumstances, financial circum-
stances, friendships, family relations, leisure time, per-
sonal safety, sexual relationships, mental health and
physical health. There are 4 questions that can be an-
swered with “yes” or “no”, the other items will be scored
on a 7-points scale: “could not be worse”, “dissatisfied”,
“mostly dissatisfied”, “neutral”, “mostly satisfied”, “satis-
fied” or “could not be better”. A total score will be calcu-
lated whereby a higher score indicates a higher quality
of life.
Individual Recovery Outcome Counter (I-ROC) In this
study we will use the I-ROC, a 12-item self-rating scale
Fig. 1 Study procedure. Patients who score above the cut-off score for any type of sleep disorder on the Holland Sleep disorders Questionnaire
(HSDQ+) will be invited for extensive diagnostic evaluation, followed by patient-targeted sleep treatment. Those participants will be randomly
divided in one of two conditions: in TAU+SI-T0 sleep diagnosis and sleep intervention (SI) will start immediately (T0), in addition to the treatment
as usual (TAU). In TAU+SI-T1 sleep diagnosis and SI will start after 6 months (T1). Questionnaires will be filled in at T0, T1 and T2 (after 12 months),
measuring sleep, general functioning, specific mental disorder symptoms, and quality of life. For patients scoring below the cut-off score for a
sleep disorder (HSDQ-), participation is limited to filling out the questionnaires at T0
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designed to measure personal recovery. The I-ROC is a
valid and reliable recovery outcomes measure, with a
sufficient high internal consistency (α = .86) [26]. The
questionnaire focusses on the following themes: Mental
health, life skills, safety and comfort, physical health, ex-
ercise and activity, purpose and direction, personal net-
work, social network, valuing myself, participation and
control, self-management, and hope for future [26]. Par-
ticipants will be asked to score each item on a 6-point
Likert scale, ranging from 1 (= “never”) to 6 (= “all of
the time”), where each rating refers to the past 3-month
period. A higher total score intents to represent a greater
level of personal recovery.
General functioning
To assess changes in general functioning, the Outcome
Questionnaire (OQ-45) [27] will be employed. In this
45-item self-report questionnaire participants will be
asked to answer the items based on how they have felt
over the past week on a 5-point Likert scale, ranging
from 0 (= “never”) to 4 (= “always”). The OQ-45 is a val-
idated instrument with good internal consistency
(α = .93) [27]. The OQ-45 was shown to be sensitive to
treatment effects in heterogeneous patient samples [28].
The questionnaire originally consists of 3 different sub-
scales: 1) Subjective Distress, 2) Interpersonal Relations
and 3) Social Role. In this study we will use the Dutch
version of the OQ-45, in which an extra subscale has
been added and validated: Anxiety and Somatic Distress
[29]. The psychometric properties of the Dutch OQ-45
are adequate and similar to the original instrument [29].
The total score and the four subscale scores of the OQ-
45 will be used as outcome parameters.
Specific mental disorder symptoms
One (or more) of the following questionnaires, depend-
ing on the participant’s main DSM-5 diagnosis, will be
used to assess specific symptomatology. Total scores will
be used as outcome parameters and participants will be
invited to fill out the questionnaire at all three time
points.
Quick inventory of depressive symptomatology, self-
report (QIDS-SR16) The QIDS-SR16 [30] is a 16-item
self-report scale that will be used to assess depressive
symptomatology, in individuals with a depressive or bi-
polar disorder diagnosis. Participants are asked to an-
swer the items by selecting one out of four statements
that fitted them best in the last week. The QIDS-SR16 is
a validated instrument with good internal consistency
(α = .86) and sensitivity to symptomatic change following
treatment [30].
Altman self-rating mania scale (ASRM) The ASRM
[31] is a 5-item self-rating questionnaire that measures
mania symptoms. This questionnaire is used in individ-
uals with a bipolar disorder diagnosis, in addition to the
QIDS. In each item participants will be asked to select
one out of five statements that best summarizes the way
they felt in the last week. The ASRM is a validated scale,
with sensitivity to change following treatment [31].
Spielberger state-trait anxiety inventory, Dutch-Y
(STAI-DY) The STAI is a brief self-report scale de-
signed to measure and differentiate between anxiety as a
trait and a state. In this study a Dutch version (STAI-
DY) [32] will be used to assess anxiety symptoms in in-
dividuals with anxiety disorder diagnosis. Participants
are asked to only fill out the state section of the STAI-
DY. They will be asked to rate 20 statements on a 4-
point scale ranging from “not at all” to “very much so”.
The STAI-DY has been validated and the internal
consistency is good (α between .91 and .95) for both in-
dividuals who are treated in outpatient and inpatient
centers for mental health care [32].
Posttraumatic stress disorder checklist for DSM-5
(PCL-5) The PCL-5 [33] is a 20-item self-respond meas-
ure of PTSD symptomatology, in individuals with a
PTSD diagnosis. Participants are asked to describe their
worst stressful experience and after this, to provide a
symptom severity rating that ranges from (0=) “not at
all” to (4=) “extremely”. The PCL-5 is a psychometrically
sound instrument with good internal consistency
(α = .94) [34] and useful for detecting clinical change
over time in symptoms after treatment [35].
Adult ADHD self-report scale (ASRS-v1.1) In this
questionnaire participants are asked to rate a list of
symptoms on a 5-point scale, ranging from (0=) “never”
to (4=) “very often”, in order to assess ADHD symptoms
in individuals with an ADHD diagnosis. The ASRS ori-
ginally consists of 18 items. In this study we will make
use of a shorter form of the ASRS (ASRS-v1.1), in order
to reduce the burden to the participants. This 6-item
screening version has shown to outperform the full ver-
sion in sensitivity (68.7% versus 56.3%) and specificity
(99.5% versus 98.3%) [36].
Autism spectrum quotient (AQ-50) The AQ [37] will
be used to assess autism-related symptoms in individuals
with an ASD diagnosis. The AQ consists of 50 items
assessing personal preferences and habits. Participants
rate to what extent they agree or disagree with the listed
statements on a 4-point Likert scale with answer cat-
egories: “definitely agree”, “slightly agree”, “slightly dis-
agree”, and “definitely disagree”. The AQ is a valid and
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reliable instrument to assess individual differences in
autistic traits and the internal consistency of the Dutch
AQ is satisfactory (α = .71) [38].
PHAMOUS-basis psychosevragen This short question-
naire will be used to assess symptom severity in individ-
uals with a SSD diagnosis. Participants are asked to
indicate if they have experienced the nine listed symp-
toms in the past 14 days by answering: 0 = “no”, 1 = “yes,
probably”, or 2 = “yes”. The average item-score will be
used as outcome variable. This questionnaire is currently
being validated.
Positive and negative syndrome scale (PANSS) In
addition to the “PHAMOUS-basis psychosevragen”, in in-
dividuals with a SSD diagnosis assessments will be made
on positive and negative symptoms at T0 and T2 as part
of the ROM, using the Positive and Negative Syndrome
Scale (PANSS) [39] interview. The PANSS is a validated
7-point, 30-item rating instrument, with each point repre-
senting increasing levels of psychopathology: 1 = “absent”,
2 = “minimal”, 3 = “mild”, 4 = “moderate”, 5 = “moderate-
severe”, 6 = “severe”, and 7 = “extreme” [39].
Sleep disorder diagnosis
The sleep diagnostic process depends on the suspected
sleep disorder(s) indicated by the HSDQ. Each partici-
pant scoring positive for one or more (types of) sleep
disorder(s) will be invited for a sleep diagnostic interview
by trained psychologists. Participants will also be asked
to complete one or more short questionnaires (5–10
min) during this interview, depending on the HSDQ-
indicated sleep disorder(s). The following questionnaires
will be used: the Pittsburgh Sleep Quality Index (PSQI)
[40] for subjective quality of sleep; Insomnia Severity
Index (ISI) [41] in participants with HSDQ-indicated In-
somnia disorder; Morningness - Eveningness Question-
naire [42] in participants with HSDQ-indicated CRSD;
Epworth Sleepiness Scale (ESS) [43] in participants with
HSDQ-indicated SRBD and/or hypersomnia and; Inter-
national RLS study group rating scale (IRLS) [44] in pa-
tients with HSDQ-indicated RLS. An additional file is
added, and describes the sleep-oriented questionnaires
in more detail (see Additional file 1). In order to evaluate
the effect of sleep disorder treatment, the same ques-
tionnaires will also be filled out by the participants dir-
ectly following the sleep intervention.
The diagnostic interview takes around 30–60 min.
Hereafter, participants will be asked to wear an actigraph
(Motionwatch 8, CamNtech) for two weeks in case of
CRSD, and for one week in all other cases. This acti-
graph is a diagnostic instrument in the form of a wrist-
band that registers bodily activity in order to asses
objective sleep quality and sleep-wake pattern.
Additionally, participants will be asked to complete a
sleep diary for the same time period they wear the acti-
graph, in which they note their bedtimes, estimated sleep
latency, total sleep duration, sleep quality, and number
of awakenings. If further information is needed for diag-
nosis, additional diagnostic measurements will be made,
such as polysomnography, Dim Light Melatonin Onset
(DLMO) measurement to determine the circadian
rhythm in CRSD and Multiple Sleep Latency Test
(MSLT) to evaluate hypersomnia. For diagnosing sleep
disorders, ICSD-3 criteria [4] will be followed. Final
diagnosis will be made during a multidisciplinary con-
sultation with a somnologist, a somno-technologist and
psychologists. Complex cases will additionally be dis-
cussed with a neurologist, pulmonary-specialist, and/or
psychiatrist.
Sleep disorder treatment
Based on the sleep diagnosis, a sleep treatment plan will
be made by the multidisciplinary team described above.
Furthermore, the treatment plan will be discussed with
the participant’s mental health professional to ensure it
fits with the patient’s overall treatment plan. Examples
of standard sleep interventions are: psychotherapies, (e.g.
CBT-I and IRT), chronotherapy (e.g. light and dark ther-
apy), treatment for sleep related breathing disorders (e.g.
continuous positive airway pressure (CPAP)) and/or
medication)(overview provided in Table 1). All sleep dis-
order treatments are well established and follow inter-
national guidelines. Also, current treatments were
evaluated by patient representatives from each mental
disorder diagnostic group and by experienced practi-
tioners of the sleep centre, prior to the start of the study.
Where appropriate, treatments were adjusted to de-
crease the burden on the participants, to increase treat-
ment compliance, and/or efficacy. Treatments will be
delivered by trained psychologists and in case of medica-
tion use and/or advice a psychiatrist will be involved in
the treatment as well.
Sample size calculations
Power analysis were performed using G*Power software
[45]. Based on previous studies [18, 46], we aim at an ef-
fect size of 0.4 (Cohen’s d) for the outcome variables
“quality of life”, “general functioning” and “mental dis-
order specific symptoms”. Power analysis based with an
α of .05 and a power of .8, resulted in a required group
size of 48 patients per diagnostic group (24 TAU+SI-T0
and 24 TAU+SI-T1). Due to limitations in recruitment
capacity in less prevalent disorders, differences across
both sexes will only be examined in the relatively high
prevalent disorders: depression and PTSS. Power ana-
lysis with a 2 × 2 experimental group design (TAU+SI-
T0 versus TAU+SI-T1; and males versus females) as
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between subject factors and the three time points as
within subject factors suggests that with an α of .05 and
a power of .8 a group size of 92 per group (46 TAU+SI-
T0 and 46 TAU+SI-T1) would be sufficient. This ana-
lysis assumes an equal sex distribution. Overall, a total
of 472 participants will be included in this study (over-
view provided in Table 2).
Statistical analyses
Data exploration/ missing data
Separate analyses will be performed for the different
questionnaires, using SPSS (version 23) and R software.
If data are not normally distributed, data transforma-
tions will be performed. A data management plan was
generated using online software and can be found at
DMPonline (https://dmponline.dcc.ac.uk/).
If a participant stops participation halfway the study or
if a specific questionnaire is missing at a specific time
point this will be dealt with as follows: if the last data
point (T2) is missing, the participant will be included in
the analysis for the prevalence and in any analysis fo-
cussed on de comparison between T0 and T1. For those
participants that are missing a complete questionnaire at
T1, but do have the T2 measurements, T1 will be
treated as a missing data point and imputed using
multiple imputation. If a participant is missing both the
T1 and T2 data point, this participant will only be in-
cluded in the prevalence analysis.
Because we make use of a delayed start for the sleep
treatment in the TAU-SI-T1 group, there is a possibility
that some participants in the TAU-SI-T1 control group
score above the cut-off score for a sleep disorder on the
HSDQ at T0, but below the cut-off score for a sleep dis-
order at T1. In this case, these participants will be in-
formed about the change in their HSDQ score, and that
they are no longer eligible for sleep disorder treatment,
and thus excluded from the treatment part of the study.
Another scenario is that a participant scores above a
cut-off score of the HSDQ, but that the sleep disorder is
not confirmed in the diagnostic evaluation. In this case,
the participant will also be excluded from the treatment
part of the study.
Prevalence
Descriptive statistics will be used to assess the preva-
lence of the different sleep disorders over the entire
study population and within different subgroups of men-
tal disorders. The prevalence of the six different types of
sleep disorders (based on the HSDQ indicated diagnosis)
will be calculated as a frequency for the total study
Table 1 Overview of indicated sleep interventions
Sleep disorder Treatment options
Insomnia CBT-I; lifestyle advise; adjustments of medication, treatment with medication
OSAS Lifestyle advise; CPAP; positional trainer; mandibular repositioner appliance
(MRA); adjustments of medication
Delayed Sleep Phase Syndrome (DSPS) Lifestyle advise; chronotherapy; treatment with melatonin
RLS/PLMD Lifestyle advise; adjustments of medication; treatment with medication
Hypersomnia Daily scheduled nap; lifestyle advise; treatment with medication
Nightmare disorder IRT; Eye Movement Desensitization and Reprocessing (EMDR); treatment with
medication; medication advise







Total required number per
diagnostic subgroup
% of total population needed
to include
Depression 17 Yes 46 92 15.0
Bipolar
disorder
3 No 24 48 44.4
Anxiety
disorder
10 No 24 48 13.3
PTSD 15 Yes 46 92 18.1
ADHD/ADD 9 No 24 48 14.7
ASD 4 No 24 48 33.1
SSD 5 No 24 48 26.7
Personality
disorder
6 No 24 48 22.3
Total 236 472
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population and for the eight mental disorder diagnostic
groups separately. Differences in prevalence between the
various mental disorder diagnostic groups will be com-
puted using chi-square and/or Phi or Cramer-V analysis.
The Standardized incidence ratio (SIR) will be calculated
for the clinical population relative to reported prevalence
of the different sleep disorders in the general population.
Effect of sleep disorder treatment
Nearly all sleep disorders induce disturbed sleep and
consequently result in a sleep deficit. We hypothesize
that the sleep deficit, rather than the underlying dis-
order, may be most influential on the added burden of
the sleep disorder on the patient’s mental well-being.
Therefore, in the analysis of the effects of added sleep
interventions, no distinction will be made between the
different all types sleep disorders and all treatments will
be lumped together. The effects of added sleep interven-
tion in all participants with a sleep disorder will be
assessed at six and twelve months by comparison of
treatment (TAU-SI-T0 and TAU-SI-T1) groups over
time (T0, T1, and T2). Secondary analysis will focus on
the interaction between treatment effect and sex differ-
ences. For statistical evaluation linear mixed models,
separate for all outcome parameters, will be employed.
A stepwise approach will be followed in which first re-
sults for crude models will be taken, after which models
including potential confounders such as age, sex, and so-
cial demographic parameters are run.
These analyses will be performed in the total popula-
tion for the quality of life and general symptom outcome
parameters, and in the eight mental disorder diagnostic
subpopulations (depressive disorder, bipolar disorder,
anxiety disorder, PTSD, AD(H)D, ASD, SSD and person-
ality disorder) for the specific mental disorder symptom
parameters. Due to power limitations, secondary analysis
will only be performed within the more prevalent disor-
ders: depression and PTSD.
Discussion
The overarching objective of this project is to develop
and evaluate a procedure for early detection and treat-
ment of sleep disorders in individuals with mental disor-
ders in order to augment therapeutic outcome and
enhance well-being.
The first aim of this study is to gain insight into the
prevalence of the different sleep disorders as a function
of specific mental disorders. If we would observe a high
prevalence of a certain sleep disorder in connection to a
particular mental disorder, extra attention can be paid
and extra resources could be allocated to the detection
and treatment of that specific sleep disorder within indi-
viduals who are diagnosed with this particular mental
disorder. Additionally, the observation of a high
prevalence of a certain sleep disorder in individuals with
a specific mental disorder profile could lead to the iden-
tification of novel etiological pathways underlying the re-
spective sleep disorders. This may improve mental
health care and provide novel therapeutic targets.
The second aim of this project is to test whether sleep
disorder treatment can improve the outcome of com-
mon treatment for mental disorders, as well as individ-
ual’s quality of life. For some mental disorders,
treatment of a co-occurring sleep disorder might signifi-
cantly improve mental well-being, whereas for other dis-
orders it might have less incremental effects. That
treatment of sleep disorders can improve mental health
of individuals with mental disorders became evident in
studies investigating treatment of insomnia in individ-
uals with depressive disorder [15–18]. However, for
other mental disorders and other sleep disorders, the im-
portance of sleep disorder treatment for treatment out-
come has only rarely been investigated. Thus, the
current project will provide important complementary
data allowing evaluation of the clinical relevance of
treating sleep disorders in the context of distinct mental
disorders.
This is one of the first studies to test the prediction
that early identification and treatment of sleep disorders
in addition to treatment as usual for mental disorders
will result in superior treatment outcome. As an import-
ant strength, this study will include a large population
with a wide variability in mental disorders and comorbid
sleep disorders. Another asset of this project is that
standard interventions for sleep disorders were adapted
to vulnerable psychiatric populations, which will increase
compliance and treatment efficacy. We anticipate that
this study will contribute to both patient care as well as
to our scientific understanding of the complex inter-
action between mental disorders and sleep disorders.
The goal of this project is to develop an effective
paradigm for the early detection and treatment of co-
morbid sleep disorders for mental health care, in
order to improve therapeutic outcome and patients’
well-being. To optimize the impact of such additional
intervention and to prevent a detrimental impact of
prolonged untreated sleep disorders on the course of
individuals’ mental disorders, the current project fo-
cusses on the early detection and treatment of sleep
disorders in individuals who apply for treatment for
mental disorders. This randomized controlled trial
will result in a database including patients with a var-
iety of mental health problems and a variety of co-
occurring sleep disorders. This provides us with the
unique opportunity to gain insight into the reciprocal
relationship between numerous mental and sleep dis-
orders, and the effects of sleep disorder treatment on
mental health. In doing this, we aim to increase
Heege et al. BMC Psychiatry          (2020) 20:331 Page 8 of 10
knowledge and improve care in individuals with men-
tal disorders and comorbid sleep disorders.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12888-020-02737-3.
Additional file 1. Description of questionnaires used in the sleep
disorder diagnosis.
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